The estimated Net Worth of Alan Colowick is at least $316 mil dollars as of 1 July 2020. Alan Colowick owns over 7,500 units of Personalis Inc stock worth over $44,625 and over the last 18 years he sold PSNL stock worth over $0. In addition, he makes $271,811 as Independent Director at Personalis Inc.
Alan has made over 2 trades of the Personalis Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of PSNL stock worth $34,050 on 1 July 2020.
The largest trade he's ever made was exercising 7,500 units of Personalis Inc stock on 1 July 2020 worth over $34,050. On average, Alan trades about 600 units every 2 days since 2006. As of 1 July 2020 he still owns at least 7,500 units of Personalis Inc stock.
You can see the complete history of Alan Colowick stock trades at the bottom of the page.
Dr. Alan B. Colowick M.D. serves as Independent Director of the Company. Dr. Colowick has served as a Partner at Sofinnova Investment, Inc., a clinical stage life sciences venture capital firm. From February 2010 to April 2017, Dr. Colowick held various positions, including Executive Vice President, at Celgene Corporation, a pharmaceutical company. From February 2008 to January 2010, Dr. Colowick served as the Chief Executive Officer of Gloucester Pharmaceuticals Inc., an early stage cancer pharmaceutical company, until its acquisition by Celgene Corporation in January 2010. From October 2006 to February 2008, Dr. Colowick served as President, Oncology at Geron Corporation, an early stage pharmaceutical company. Earlier in his career, Dr. Colowick served in various capacities at Amgen Inc., a biopharmaceutical company. Dr. Colowick has served on the board of directors of Human Longevity, Inc., a genomics-based health intelligence company, since June 2016, and has served on the board of directors of Principia Biopharma Inc., a biopharmaceutical company, since February 2017. Dr. Colowick previously served on the board of directors of Achaogen, Inc., a biopharmaceutical company, from August 2015 to August 2017, and on the board of directors of Dimension Therapeutics, Inc., a biopharmaceutical company, from August 2015 to November 2017. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University School of Medicine, and an M.P.H. from the Harvard School of Public Health. Dr. Colowick was selected to serve on our board of directors because of his educational background in sciences, as well as financial understanding of the biotechnology industry gained from his investing experience.
As the Independent Director of Personalis Inc, the total compensation of Alan Colowick at Personalis Inc is $271,811. There are 10 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.
Alan's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci y Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: